FDA approves Perrigo, Cobrek scalp psoriasis treatment

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

Perrigo said that Cobrek, with which it is partnering, had received approval for betamethasone validate foam in the 0.12% strength. The drug is a generic version of Luxiq foam, made by GlaxoSmithKline subsidiary Stiefel Labs, and is used to treat corticosteroid-responsive skin conditions of the scalp, also known as scalp psoriasis.

The branded version of the drug has annual sales of about $40 million, according to Perrigo.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.